Subtitle: Neoantigen-Specific Reagents for Glioblastoma & Solid Tumor Immunotherapy Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EGFR vIII drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EGFR vIII ECD-Fc Fusion Protein Sequence Verified at de2-7 Junction (GVGE neo-epitope). High Purity (>95%), Endotoxin <1 EU/µg. HEK293 Expressed (Native Glycosylation). |
View EGFR vIII Products |
| Counter-Screen (WT EGFR) | Wild-Type EGFR ECD-Fc Protein For selectivity screening against native full-length receptor. Sequence Verified. |
View EGFR Products |
| Gene Delivery | EGFR vIII Lentivirus Premade Particles Full-length mutant ORF (de2-7) for stable cell line construction. High Titer (>10^8 TU/ml), Puromycin Selectable. Essential for membrane conformation preservation. |
View EGFR vIII Products |
| Benchmark Ab | Anti-EGFR vIII (de2-7 Junction Specific) Recombinant antibody recognizing unique GVGE neo-epitope. Sequence-verified variable regions. |
View EGFR vIII Products |
| Validator | EGFR vIII siRNA Set For knockdown verification of target specificity in transient/stable cell lines. |
View EGFR vIII Products |
| Pathway Partner | MET (c-Met) Compensatory signaling pathway mediating resistance in GBM. |
View MET Products |
| Downstream Node | PIK3CA Mutant Proteins For downstream pathway activation studies (H1047R, E545K). |
View PIK3CA Products |
| Related Target A | IL13RA2 Synergistic target for Multi-specific CAR-T development in Glioblastoma. |
View IL13RA2 Products |
| Related Target B | HER2 Co-expressed target for combination immunotherapy approaches. |
View HER2 Products |
Critical Assay Challenges & Technical Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Tumor Specificity vs. Wild-Type Safety | Precision truncated ECD-Fc proteins (Exon 2-7 deletion structurally verified) to ensure exact tumor-specific epitope presentation. |
| Junction-Specific Epitope Verification (GVGE motif) | Mass Spectrometry Verified de2-7 Ligation Site. Guaranteed exposure of neo-epitope not present in WT EGFR. |
| Cell Surface Expression & Conformation (CAR-T/ADC) | Lentivirus for stable cell line generation. Preserves native membrane topology and glycosylation patterns essential for conformational antibody screening and accurate Flow Cytometry. |
| Internalization Efficiency (ADC Development) | Cell-Based Internalization Assay Ready. Lentivirus-transduced cells maintain constitutive signaling and internalization kinetics comparable to native glioma lines. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
| Species Cross-Reactivity (Syngeneic Models) | Human/Mouse Ortholog Available. Mouse EgfrvIII shares identical junction sequence; proteins available for preclinical model validation. |
Live EGFR vIII R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
EGFR vIII represents one of the most validated tumor-specific neoantigens in oncology, driven by its absolute restriction to malignancy and absence from normal tissues. Following the Phase 3 setbacks of Depatuxizumab mafodotin (AbbVie) and Rindopepimut (Celldex), the field has pivoted toward cellular immunotherapies, including CAR-T and CAR-Macrophage modalities, with increasing interest in bispecific T-cell engagers (BiTEs) targeting the de2-7 junction. Major players are shifting focus from traditional mAbs and peptide vaccines to multi-specific approaches (e.g., dual-targeting CAR-Ts) and payload delivery optimization across the blood-brain barrier (BBB) to treat Glioblastoma Multiforme (GBM) effectively. As first-generation autologous CAR-T therapies face manufacturing and persistence challenges in the solid tumor microenvironment, next-generation R&D is targeting armored CAR constructs with cytokine secretion (IL-15, IL-12) and combination regimens with checkpoint inhibitors. The critical unmet need remains antigen heterogeneity—assay solutions must now distinguish between EGFR vIII expression levels and WT EGFR amplification to predict therapeutic windows accurately.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / Cell Therapy | Novartis, Mustang Bio, CARsgen, Carisma Therapeutics, City of Hope | Glioblastoma (GBM) | FACS Binding Assay; Stable Cell Line Generation (Lentivirus) for antigen density titration and exhaustion studies. |
| ADC | AbbVie (Historical), Taiho Oncology, GeneQuantum | GBM, NSCLC (EGFRvIII+) | Internalization Assay; WT Selectivity Panel (EGFR vIII vs WT proteins). |
| Bispecific Antibodies | Amgen, Regeneron, AstraZeneca, Academic Consortiums | Brain Malignancies, Solid Tumors | Selectivity Screening; Cross-reactivity Profiling with WT EGFR subfamily (ERBB2, ERBB3, ERBB4). |
| Peptide Vaccine | Celldex (Rindopepimut - discontinued), NCI | GBM (Maintenance) | Immunogenicity Validation (MHC binding assays require high-purity protein). |